Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
Public ClinicalTrials.gov record NCT03989362. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
Study identification
- NCT ID
- NCT03989362
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2019
- Primary completion
- Mar 14, 2022
- Completion
- Mar 14, 2022
- Last update posted
- Sep 9, 2022
2019 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| University of Southern California Medical Center | Los Angeles | California | 90033 | — |
| Christiana Care Health Services | Newark | Delaware | 19713 | — |
| Florida Cancer Specialists Sarasota Cattlemen | Sarasota | Florida | 34232 | — |
| University of Maryland - Marlene and Stewart Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| The Valley Hospital | Ridgewood | New Jersey | 07450 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Southeastern Medical Oncology Center | Clinton | North Carolina | 28328 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Allegheny Health Network Research Institute | Pittsburgh | Pennsylvania | 15212 | — |
| Lifespan Cancer Institute | Providence | Rhode Island | 02903 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of The Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03989362, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03989362 live on ClinicalTrials.gov.